| Literature DB >> 26579381 |
Palaniselvam Kuppusamy1, Mashitah M Yusoff1, Gaanty Pragas Maniam1, Solachuddin Jauhari Arief Ichwan2, Ilavenil Soundharrajan3, Natanamurugaraj Govindan1.
Abstract
Colon cancer is a world-wide health problem and the second-most dangerous type of cancer, affecting both men and women. The modern diet and lifestyles, with high meat consumption and excessive alcohol use, along with limited physical activity has led to an increasing mortality rate for colon cancer worldwide. As a result, there is a need to develop novel and environmentally benign drug therapies for colon cancer. Currently, nutraceuticals play an increasingly important role in the treatment of various chronic diseases such as colon cancer, diabetes and Alzheimer׳s disease. Nutraceuticals are derived from various natural sources such as medicinal plants, marine organisms, vegetables and fruits. Nutraceuticals have shown the potential to reduce the risk of colon cancer and slow its progression. These dietary substances target different molecular aspects of colon cancer development. Accordingly, this review briefly discusses the medicinal importance of nutraceuticals and their ability to reduce the risk of colorectal carcinogenesis.Entities:
Keywords: 5-FU, 5-fluorouracil; ACC, acetyl CoA carboxylase; ACF, aberrant crypt foci; ACL, ATP-citrate lyase; ASTX, astaxanthin; COX-2, cyclooxygenase 2; Colon cancer; DHA, decahexaenoic acid; DMH, 1,2-dimethylhydrazine; DR, death receptor; EGCG, epigallocatechingallate; EPA, eicosapentaenoic acid; FAS, fatty acid synthase; GADD, growth arrest and DNA damage; HMG-CoA, 3-hydroxy-3-methyl-glutaryl CoA; HUVEC, human umbilical vein endothelial cell; IGF, insulin-like growth factor; IL, interleukin; LDH, lactate dehydrogenase; MMP, matrix metallo-proteins; Marine organisms; NF-κB, nuclear factor-kappa B; Nutraceuticals; PRAP, prolactin receptor associated protein; Plant derivatives; TCA, tricarboxylic acid cycle; TNF, tumor necrosis factor; TRAIL, tumor necrosis factor-related apoptosis-induced ligand; Therapeutics; VEGF, vascular endothelial growth factor
Year: 2014 PMID: 26579381 PMCID: PMC4629076 DOI: 10.1016/j.apsb.2014.04.002
Source DB: PubMed Journal: Acta Pharm Sin B ISSN: 2211-3835 Impact factor: 11.413
Figure 1Different classes of nutraceuticals and their uses.
Figure 2The mortality and incidence rate of colon cancer in the years 2002–2012.
Figure 3Biochemical metabolic response of colon cancer cells. The proposed mechanism of colorectal tumorigenesis: MDH, malate dehydrogenase; PHD, prolyl hydroxylase; HRE, hypoxia-responsive element; FIH-1, factor inhibiting HIF-1; TAD-C, C-terminal transcriptional activation domain; UGP2, UDP-glucose pyrophosphorylase 2; GSK3, glycogen synthetase kinase 3; ECM, extracellular matrix; pVHL, von Hippel–Lindau protein; TCA, tricarboxylic acid. Red upward pointing arrows and green downward pointing arrows denote the up-regulation and down-regulation of enzymes of metabolic pathways, respectively. All altered proteins found in the present study are highlighted as follows: up-regulated proteins are in red, and down-regulated proteins are in blue.
Figure 4Structures of clinically important secondary metabolite used in colon cancer treatment.
Nutraceuticals effectively control the progression of colon cancer cell.
| Nutraceuticals | Molecular mechanism | Cancer cell line | Ref. |
|---|---|---|---|
| Antiproliferation, oxidative phosphorylation | HCT-116 | ||
| Silbinin | Reduced cell growth | HT-29 | |
| Fenugreek | Cytokines, redox reactions | HT-29 | |
| Curcumin (turmeric) | Stimulation of MAPk, Plsk/Akt | HT29 | |
| Iron foods | Transferrin receptor (TfR1) | Cao-2, HCT-116 | |
| Graph seed | Control the signaling related epigenetics, oncogene expression | HCT-116 | |
| Zerumbone | Upregulation of DR4 and DR5 MMP-9, Cdc family | HCT-116 | |
| Allicin | Inhibit the over expression TNF- | HCT-116 | |
| Rhizochalin | Caspase-3 and PRAP activation | HT-29 | |
| Fucoxanthin | Induce apoptosis | Caco-2, HT-29 | |
| Protein and peptides (milk) | Hypoproliferation of epitheliam | HCT-116 | |
| Garcinol | Inhibition of tyrosine phosphorylation | HT-29 | |
| Xanthohumol | Upregulation of caspase-3, -8, -9 | HT-29 | |
| Boswellic acid | Decrease in cyclin D1 expression | HT-29 | |
| Induced cell cycle arrest at the G1/S phase | HT-29 | ||
| Quercetin | Inhibition of cyclin D1 expression | SW 480 | |
| Fisetin | Activation of NF- | HT-29 |
Different dietary nutraceuticals using for anticolon cancer and preventive medicine
| Secondary metabolites | Sources | Cancer cell lines | Applications | Ref. |
|---|---|---|---|---|
| Oleuropein | Olive tree leaves | Colon cancer cell line | Protect DNA damage | |
| Vitamin D (25-hydroxy vitamin D) | Milk and milk based products | Colon cancer cell line | Reducing the colon cancer development | |
| Procyanidins | Apple fruit | SW 480, SW 620 | Differentiation of apoptosis function | |
| Scallian | Allium fistulosum | CT-26 | Effect of inhibit colorectal tumor growth | |
| Centella asiatica crude extract | Whole plant | Caco-2 colon cancer | Regulate the cell cycle | |
| Salograriolide A | HCT-116 | Reduce the colon tumor formation | ||
| Avenanthramides | Oats | HCT-116 | Attenuates of colon cancer cells | |
| Whole plant | HCT-116 | Control the p53 tumor gene | ||
| Crude Lentinus edodes extract | Mushroom fruit bodies | HCT-116 | Regulate the apoptosis of cancer cells | |
| Resveratrol | Grapes, wines | HCT-116 | Stimulate p53 gene for apoptosis | |
| Conjugated linolinic acid | Probiotic bacteria | Colorectal cancer | Enhance apoptosis of tumor cells | |
| Crude phenolics extract | HCT-116 | Induction of IL-3 expression | ||
| Garlic crude extract | HT-29 | Inducing apoptotic cell death |